Loading...
Variations in genomic testing in non-small cell lung carcinoma: a healthcare professional survey of current practices in the UK
Baijal, S. Crosbie, P. Fenemore, Jackie Desai, K.
Baijal, S.
Crosbie, P.
Fenemore, Jackie
Desai, K.
Citations
Altmetric:
Abstract
This survey aims to understand the current UK practice for non-small cell lung carcinoma (NSCLC) and identify barriers that may impact patient treatment and outcomes. In March-June 2021, 57 interviews were conducted with healthcare professionals involved in the secondary care management of patients with NSCLC. Most respondents performed genetic testing at onsite and non-genomic laboratory hub (GLH) offsite locations. The most common genetic tests were EGFR T790M variant (100%), EGFR exon 18-21 covered (95%) and BRAF (93%). No targeted therapy (TT) available (69%), lack of access to a TT (54%) or excessive molecular testing turnaround times (39%) were the most common reasons for using an immuno-oncology therapy over a TT in the first-line setting. The survey highlights variation in mutation testing practices across the UK, which may impact treatment decisions and contribute to health outcome inequality.
Description
Date
2023
Publisher
Collections
Files
Keywords
Type
Article
Citation
Baijal S, Crosbie P, Fenemore J, Desai K. Variations in Genomic Testing in Non-small Cell Lung Carcinoma: A Healthcare Professional Survey of Current Practices in the UK. Oncologist. 2023 Jun 13. PubMed PMID: 37310183. Epub 2023/06/13. eng.